journal cover

The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death

Progress in Cardiovascular Diseases

May 14, 2008

Ganesh S Kamath, Suneet Mittal

Abstract

Sudden cardiac death (SCD) accounts for more than 300,000 deaths annually in the United States alone. The utility of antiarrhythmic drugs in survivors of SCD (secondary prevention) is limited because of their incomplete efficacy and long-term toxicity. Efforts to target primary preventi...read more

Mentioned in this Paper

Azimilide
Andersen Syndrome
Amiodarone
Action Potentials
Syncope (amphibian)
Ventricular Dysfunction, Left
Sotalol
Anti-Arrhythmia Agents
Antiarrhythmic [EPC]
Shock
30
Paper Details
References
  • References22
  • Citations12
123
  • References22
  • Citations12
12

Similar Papers Found In These Feeds

Ventricular Arrhythmias

Ventricular arrhythmias are abnormal heart rhythms that originate in the lower part of the heart. Find the latest research on ventricular arrhythmias here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Heart Rhythm & Arrythmias

Heart arrhythmias, also known as irregular heartbeat or cardiac dysrhythmia, are a group of conditions where the heartbeat is irregular (dysrhythmia), too slow (bradycardia), or too fast (tachycardia). Discover the latest research on heart rhythm and arrythmias here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

HFrEF

Heart failure with reduced ejection fraction (HF-rEF) is responsible for high costs and increased rates of hospital admissions along with high mortality and morbidity risks. Only treatment for HF-rEF has been shown to be efficacious compared to HF-pEF which currently has no useful treatment options. Here is the latest research on HF-rEF.

HFpEF

HF-pEF is associated with left ventricular diastolic dysfunction and concentric left ventricular hypertrophy and has significant mortality and morbidity. The heterogeneity of the disease has resulted in the failure of any drugs for the treatment of HF-pEF. Here are the latest discoveries pertaining to this disease.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Journal of Cardiovascular Pharmacology and Therapeutics

Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs

Journal of Cardiovascular Pharmacology and TherapeuticsSeptember 19, 2007
Steven Singh, Matthew M Murawski
Journal of the American College of Cardiology

Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial

Journal of the American College of CardiologyOctober 14, 2008
Paul DorianShock Inhibition Evaluation with Azimilide Investigators
© 2020 Meta ULC. All rights reserved

The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death

Progress in Cardiovascular Diseases

May 14, 2008

Ganesh S Kamath, Suneet Mittal

PMID: 18474286

DOI: 10.1016/j.pcad.2007.12.001

Abstract

Sudden cardiac death (SCD) accounts for more than 300,000 deaths annually in the United States alone. The utility of antiarrhythmic drugs in survivors of SCD (secondary prevention) is limited because of their incomplete efficacy and long-term toxicity. Efforts to target primary preventi...read more

Mentioned in this Paper

Azimilide
Andersen Syndrome
Amiodarone
Action Potentials
Syncope (amphibian)
Ventricular Dysfunction, Left
Sotalol
Anti-Arrhythmia Agents
Antiarrhythmic [EPC]
Shock
30

Similar Papers Found In These Feeds

Ventricular Arrhythmias

Ventricular arrhythmias are abnormal heart rhythms that originate in the lower part of the heart. Find the latest research on ventricular arrhythmias here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Related Papers

Journal of Cardiovascular Pharmacology and Therapeutics

Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs

Journal of Cardiovascular Pharmacology and TherapeuticsSeptember 19, 2007
Steven Singh, Matthew M Murawski
Journal of the American College of Cardiology

Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial

Journal of the American College of CardiologyOctober 14, 2008
Paul DorianShock Inhibition Evaluation with Azimilide Investigators
Paper Details
References
  • References22
  • Citations12
123
  • References22
  • Citations12
12
/papers/the-role-of-antiarrhythmic-drug-therapy-for-the/18474286